Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11213886 | 0.81 | TDP1 (0.44) | TSHRMEN1KMT2ATDP1LMNA | |
| SCHEMBL356446 | 0.81 | ALDH1A1 (0.39) | TSHRTDP1LMNACYP3A4 | |
| SCHEMBL31693092 | 0.81 | ALDH1A1 (0.39) | TSHRTDP1LMNACYP3A4 | |
| SCHEMBL18465494 | 0.81 | ALDH1A1 (0.39) | TSHRTDP1LMNACYP3A4 | |
| SCHEMBL23200430 | 0.80 | TSHR (0.40) | TSHRMEN1KMT2ATDP1LMNA | |
| Water SCHEMBL2996871 | 0.79 | ALDH1A1 (0.37) | TSHRTDP1LMNACYP3A4 | |
| SCHEMBL11521228 | 0.79 | TSHR (0.43) | TSHRTDP1LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL28975958 | 0.79 | ALDH1A1 (0.37) | TSHRTDP1LMNACYP3A4 | |
| SCHEMBL11793343 | 0.79 | TSHR (0.55) | TSHRTDP1USP2LMNACYP3A4 | |
| SCHEMBL4188929 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030868-B2 | Prodrugs of CGRP antagonists | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2021-12-23 | — | — | US | disclosed |
| EP-3863629-A1 | PRODRUGS OF CGRP ANTAGONISTS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-112888438-A | Prodrugs of CGRP antagonists | 拜尔哈文制药股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395223-A1 | PRODRUGS OF CGRP ANTAGONISTS | CALCRL, CALCA, CALCB | TSHR 1421/4885MEN1 1015/4885KMT2A 3669/4885 |
| US-12030868-B2 | Prodrugs of CGRP antagonists | CALCRL, CALCA, CALCB | TSHR 1421/4885MEN1 1015/4885KMT2A 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.